Despite the controversial results about the benefit of a CYP2D6 guided treatment in Tamoxifen breast-cancer treated patients, the heterogeneous results seem to point to a benefit being yielded from CYP2D6 determination in a homogeneous subset of patients [50]. The gene discussed is CYP2D6; the disease is breast carcinoma.